Drug Industry, Drugmaker | featured news

As drug industry’s influence over research grows, so does the potential for bias

Drug Industry

For drugmaker GlaxoSmithKline, the 17-page article in the New England Journal of Medicine represented a coup. The 2006 report described a trial that compared three diabetes drugs and concluded that Avandia, the company’s new drug, performed best.

 

Subscribe to this RSS topic: Syndicate content